RxDoctor Payments DataLook up a doctor →

Sudarone Thihalolipavan, MD

Clinical Cardiac Electrophysiology · Little Rock, ARNPI 1528220050

Payments from drug & device makers

$1,007,631in general payments, 2019–2025

Across 969 payments — averaging $1039.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$932K
  • Abbott$38K
  • Biosense Webster, Inc.$12K
  • Impulse Dynamics (USA) Inc.$10K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • AOP Health US, LLC$1K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$19,36325%
  • Speaking & faculty fees$17,44323%
  • Travel & lodging$4,8726%
  • Food & beverage$35,21646%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007,631 in reported general payments places this provider in the 85th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.

See all clinical cardiac electrophysiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,099,057
Medicare patients
721
Services billed
7,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$198,931
EntrestoSacubitril/Valsartan101$114,279
JardianceEmpagliflozin56$76,156
MultaqDronedarone Hcl38$52,770
XareltoRivaroxaban32$38,250
FarxigaDapagliflozin Propanediol11$16,065
Metoprolol Succinate348$3,696
Mexiletine Hcl18$2,382
SotalolSotalol Hcl143$2,194
Carvedilol150$1,366
Midodrine Hcl21$1,208
Rosuvastatin Calcium113$1,159
Losartan Potassium141$1,128
Fludrocortisone Acetate31$1,036
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$198,931183 claims
NovartisEntresto$769$114,279101 claims
Boehringer IngelheimJardiance$205$76,15656 claims
Sanofi-aventis U.S. LLCMultaq$75$52,77038 claims
Johnson & JohnsonXarelto$423$38,25032 claims
AstraZenecaFarxiga$347$16,06511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.

Other clinical cardiac electrophysiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →